What is the recommended follow-up schedule for a patient with moderately severe major depressive disorder?

Follow-Up Schedule for Moderately Severe Major Depression

Patients with moderately severe major depressive disorder should be assessed within 1-2 weeks of initiating antidepressant therapy, then regularly throughout the acute treatment phase, with treatment modification at 6-8 weeks if inadequate response occurs. 1

Initial Monitoring Phase (First 1-2 Months)

The American College of Physicians provides strong recommendations for close monitoring beginning within 1-2 weeks of treatment initiation 1. This timing is critical because:

• Suicide risk is highest during the first 1-2 months of antidepressant treatment 1
• The FDA specifically advises close monitoring for increases in suicidal thoughts and behaviors during this period 1
• Early adverse effects (agitation, irritability, unusual behavioral changes) may indicate worsening depression 1

What to Assess at Each Visit:

At every follow-up contact, systematically evaluate:

1. Ongoing depressive symptoms (using standardized tools like PHQ-9)
2. Suicide risk (direct questioning required)
3. Adverse effects from treatment (including sexual dysfunction, GI symptoms, activation)
4. Treatment adherence (medication taking, therapy attendance)
5. New or ongoing environmental stressors 2

Important caveat: While in-person visits are ideal within the first week of treatment initiation 2, telephone contact is equally effective for monitoring adverse events and can improve adherence when in-person visits are not feasible 2.

Treatment Response Assessment (6-8 Weeks)

Modify treatment if inadequate response occurs within 6-8 weeks of initiating therapy 1. This is a strong recommendation based on moderate-quality evidence. The response rate to initial antidepressant therapy may be as low as 50% 1, making this checkpoint essential.

At 6-8 weeks, if the patient shows insufficient improvement:

• Consider switching antidepressants
• Consider augmentation strategies (adding CBT or second medication)
• Evaluate for comorbid conditions, poor adherence, or ongoing stressors 2
• Consider mental health consultation 2

Continuation Phase (After Response)

Once adequate response is achieved, continue treatment for 4-9 months to prevent relapse 1. During this phase:

• Monitor monthly for 6-12 months after full symptom resolution 2
• The greatest relapse risk occurs in the first 8-12 weeks after discontinuation 2
• If discontinuing medication, provide close follow-up for at least 2-3 months 2

Special Considerations for Recurrent Depression

For patients with 2 or more prior episodes, longer treatment duration is beneficial (potentially years to lifelong) 1. These patients should be monitored for up to 2 years given high recurrence rates 2.

Practical Follow-Up Algorithm

Week 1-2: First contact (in-person or telephone) - assess tolerability, adherence, suicide risk

Weeks 2-8: Regular contacts (frequency based on severity and suicide risk) - monitor response and adverse effects

Week 6-8: Critical decision point - continue current treatment if responding, or modify if inadequate response

Months 3-12: Monthly monitoring after achieving remission

Beyond 12 months: Consider maintenance therapy for recurrent depression with ongoing monitoring

Common Pitfalls to Avoid

• Don't wait beyond 8 weeks to modify ineffective treatment - this delays recovery and increases suffering 1
• Don't discontinue monitoring once symptoms improve - relapse risk remains elevated for months 2
• Don't assume face-to-face visits are mandatory - telephone monitoring is effective and may improve adherence 2
• Don't forget to assess suicide risk at every contact, especially in the first 2 months 1

The evidence consistently supports structured, frequent monitoring in the acute phase with gradual spacing of visits during continuation treatment, always maintaining vigilance for relapse or adverse effects.